Cancer is one of the major public health problems worldwide representing the leading cause of morbidity and mortality in industrialized countries. To reduce cancer morbidity and mortality as well as to facilitate the evolution from the traditional “one size fi ts all” strategy to a new “personalized” cancer therapy (i.e., the right drug to the right patient at the right time, using the right dose and schedule), there is an urgent need of reliable, robust, accurate and validated cancer biomarker tests. Unfortunately, despite the impressive advances in tumor biology research as well as in high-powerful “omics” technologies, the translation of candidate cancer biomarkers from bench to bedside is lengthy and challenging and only a few tumor marker tests have been adopted successfully into routine clinical care of oncologic patients. This chapter provides an updated background on biomarkers research in oncology, including biomarkers clinical uses, and discusses the problems of discovery pipeline, biomarkers failures and future perspectives. © Springer Science+Business Media Dordrecht 2015.

Mordente, A., Meucci, E., Martorana, G. E., Silvestrini, A., Cancer biomarkers discovery and validation: State of the art, problems and future perspectives, in Scatena, R. (ed.), Advances in cancer biomarkers, Springer, Amsterdam 2015: 9- 26. 10.1007/978-94-017-7215-0_2 [http://hdl.handle.net/10807/72406]

Cancer biomarkers discovery and validation: State of the art, problems and future perspectives

Mordente, Alvaro;Meucci, Elisabetta;Martorana, Giuseppe Ettore;Silvestrini, Andrea
2015

Abstract

Cancer is one of the major public health problems worldwide representing the leading cause of morbidity and mortality in industrialized countries. To reduce cancer morbidity and mortality as well as to facilitate the evolution from the traditional “one size fi ts all” strategy to a new “personalized” cancer therapy (i.e., the right drug to the right patient at the right time, using the right dose and schedule), there is an urgent need of reliable, robust, accurate and validated cancer biomarker tests. Unfortunately, despite the impressive advances in tumor biology research as well as in high-powerful “omics” technologies, the translation of candidate cancer biomarkers from bench to bedside is lengthy and challenging and only a few tumor marker tests have been adopted successfully into routine clinical care of oncologic patients. This chapter provides an updated background on biomarkers research in oncology, including biomarkers clinical uses, and discusses the problems of discovery pipeline, biomarkers failures and future perspectives. © Springer Science+Business Media Dordrecht 2015.
Inglese
Advances in cancer biomarkers
978-94-017-7215-0
Springer
http://www.scopus.com/inward/record.url?eid=2-s2.0-84946916800&partnerID=40&md5=01a221ec001247a851ce74e8ce9ea650
Mordente, A., Meucci, E., Martorana, G. E., Silvestrini, A., Cancer biomarkers discovery and validation: State of the art, problems and future perspectives, in Scatena, R. (ed.), Advances in cancer biomarkers, Springer, Amsterdam 2015: 9- 26. 10.1007/978-94-017-7215-0_2 [http://hdl.handle.net/10807/72406]
File in questo prodotto:
File Dimensione Formato  
72406.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 7.29 MB
Formato Unknown
7.29 MB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/72406
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 39
social impact